Predictors for the initiation of a basal supported oral therapy (BOT) in type 2 diabetic patients under real-life conditions in Germany

Primary Care Diabetes

Volumn 6, Issue 4, 2012, Pages 329-335

  Kostev, Karel ^a   Dippel, Franz Werner ^b  

^a IQVIA   (United States)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

BOT; Diabetes; Disease Analyzer; Insulin; OAD

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BIGUANIDE DERIVATIVE; CARDIOVASCULAR AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; ISOPHANE INSULIN; LONG ACTING INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PREMIXED INSULIN; SHORT ACTING INSULIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BASAL SUPPORTED ORAL THERAPY; COHORT ANALYSIS; COMORBIDITY; DIABETES CONTROL; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; FEMALE; GERMANY; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DRUG SUBSTITUTION; FEMALE; GERMANY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84869093333     PISSN: 17519918     EISSN: 18780210     Source Type: Journal    
DOI: 10.1016/j.pcd.2012.06.001     Document Type: Article

References (36)

1. R.C. Turner, C.A. Cull, and V. Frighi Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group JAMA 281 1999 2005 2012 (Pubitemid 29254858)
2. Deutsche Diabetes Union (Hrsg.) Deutscher Gesundheitsbericht Diabetes 2009 2008 Kirchheim + Co GmbH Mainz, Germany
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 352 1998 837 853
4. R.R. Holman, S.K. Paul, and M.A. Bethel 10-year follow-up of intensive glucose control in type 2 diabetes New England Journal of Medicine 359 2008 1577 1589
5. E. Selvin, S. Marinopoulos, and G. Berkenblit Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus Annals of Internal Medicine 141 2004 421 431
6. I.M. Stratton, A.I. Adler, and H.A. Neil Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 321 2000 405 412 (Pubitemid 30609442)
7. S. Matthaei, R. Bierwirth, and A. Fritsche Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association Experimental and Clinical Endocrinology and Diabetes 117 2009 522 557
8. H.K. Berthold, I. Gouni-Berthold, and K. Bestehorn Kardiovaskuläre Risikofaktoren bei Typ-2-Diabetikern in Deutschland - ein Versorgungsparadox Deutsches Ärzteblatt 104 2007 861 867 (Pubitemid 46662387)
9. A. Icks, W. Rathmann, and B. Haastert Quality of care and extent of complications in a population-based sample of patients with type 2 diabetes mellitus. The KORA Survey 2000 Deutsche Medizinische Wochenschrift 131 2006 73 78 (Pubitemid 43194537)
10. M.E. Larkin, V.A. Capasso, and C.L. Chen Measuring psychological insulin resistance: barriers to insulin use Diabetes Educator 34 2008 511 517
11. M. Peyrot, R.R. Rubin, and T. Lauritzen Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study Diabetes Care 28 2005 2673 2679 (Pubitemid 43951158)
12. D.M. Nathan, J.B. Buse, and M.B. Davidson Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 29 2006 1963 1972 (Pubitemid 44156663)
13. R.G. Bretzel, U. Nuber, and W. Landgraf Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial Lancet 371 2008 1073 1084 (Pubitemid 351436611)
14. R.R. Holman, K.I. Thorne, and A.J. Farmer Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes New England Journal of Medicine 357 2007 1716 1730 (Pubitemid 350005153)
15. H.U. Janka, G. Plewe, and M.C. Riddle Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes Diabetes Care 28 2005 254 259 (Pubitemid 40170922)
16. M.C. Riddle, J. Rosenstock, and J. Gerich The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients Diabetes Care 26 2003 3080 3086 (Pubitemid 37339502)
17. S. Kress, F. Dippel, and K. Kostev Insulin glargin mit oralen Antidiabetika: Vorteilhafter Einstieg in die Insulintherapie. Diabetes Stoffwechsel und Herz 18 2009 3 11
18. ®, 2010.
19. P. Mullins, P. Sharplin, and H. Yki-Jarvinen Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus Clinical Therapeutics 29 2007 1607 1619 (Pubitemid 47496243)
20. E.G. Hagenmeyer, P.K. Schädlich, and ADea. Köster Lebensqualität und Behandlungszufriedenheit unter langwirksamen Analoginsulinen. Systhematischer Review Deutsche Medizinische Wochenschrift 133 2009 120 123
21. H. Hauner, T. Kohlmann, and W. Landgraf Kosten für antihyperglykämische Arznei- und Verbrauchsmittel und Therapiezufriedenheit bei Typ-2-Diabetes. Ergebnisse der Versorgungsforschungsstudie LIVE-DE Deutsche Medizinische Wochenschrift 134 2009 1207 1213
22. P.T. Donnan, D.T. Steinke, and R.W. Newton Changes in treatment after the start of oral hypoglycaemic therapy in Type 2 diabetes: a population-based study Diabetic Medicine 19 2002 606 610 (Pubitemid 35300684)
23. L.C. Groop, R. Pelkonen, and S. Koskimies Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes Diabetes Care 9 1986 129 133 (Pubitemid 16080466)
24. K.S. Polonsky, J. Sturis, and G.I. Bell Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance New England Journal of Medicine 334 1996 777 783 (Pubitemid 26089361)
25. J.A. Spoelstra, R.P. Stol, and M.C. de Bruyne Factors associated with switching from oral hypoglycaemic agents to insulin therapy Netherlands Journal of Medicine 60 2002 243 248 (Pubitemid 39089311)
26. L. Groop, C. Schalin, and A. Franssila-Kallunki Characteristics of non-insulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy American Journal of Medicine 87 1989 183 190 (Pubitemid 19201640)
27. S.B. Johnson Methodological issues in diabetes research. Measuring adherence Diabetes Care 15 1992 1658 1667
28. H. Becher, K. Kostev, and D. Schroder-Bernhardi Validity and representativeness of the "Disease Analyzer" patient database for use in pharmacoepidemiological and pharmacoeconomic studies International Journal of Clinical Pharmacology and Therapeutics 47 2009 617 626
29. B. Motheral, J. Brooks, and M.A. Clark A checklist for retrospective database studies - report of the ISPOR Task Force on Retrospective Databases Value in Health 6 2003 90 97 (Pubitemid 36403125)
30. E. Swart, and P. Ihle Health services research based on routine data generated by the SHI Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 51 2008 1093 1094
31. C. Haas, L. Zimmermann, and Bea. Höfgen Internationale Harmonisierung von Arzneimitteltechnologien: Vision und Wirklichkei Telemed Proceedings 2008 193 201
32. N. Perez, J. Moisan, and C. Sirois Initiation of insulin therapy in elderly patients taking oral antidiabetes drugs CMAJ 180 2009 1310 1316
33. J.I. Barzilay, B.R. Davis, and J.A. Cutler Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Archives of Internal Medicine 166 2006 2191 2201 (Pubitemid 44748765)
34. J.A. Spoelstra, R.P. Stolk, and E.R. Heerdink Refill compliance in type 2 diabetes mellitus: a predictor of switching to insulin therapy? Pharmacoepidemiology and Drug Safety 12 2003 121 127 (Pubitemid 36304762)
35. American Diabetes Association Standards of medical care in diabetes - 2008 Diabetes Care 31 Suppl. 1 2008 S12 S54
36. Canadian Diabetes and Association Clinical Practice Guidelines Expert Committee: clinical practice guidelines for the prevention and management of diabetes in Canada Canadian Journal of Diabetes 32 2008 53 61